Related Experiment Video
Updated: Jun 9, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe
Nina Raben1, Evelyn Ralston, Yin-Hsiu Chien
1Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892-1820, USA. rabenn@mail.nih.gov
Insights
Infants with Pompe disease show expanded lysosomes, not autophagy, unlike adults. Enzyme replacement therapy unmasks autophagy by clearing glycogen, suggesting different infant and adult Pompe disease pathogenesis.
Area of Science:
- Biochemistry
- Cell Biology
- Genetics
Background:
- Pompe disease is a lysosomal storage disorder due to acid alpha-glucosidase deficiency, impacting glycogen degradation.
- Infantile Pompe disease presents with severe cardiomyopathy and myopathy; late-onset forms primarily affect skeletal muscle.
- Autophagic inclusions are prominent in adult Pompe disease patients and mouse models.
Purpose of the Study:
- To evaluate the autophagic pathology in infants with Pompe disease before and after enzyme replacement therapy (ERT).
- To investigate the role of autophagy in infantile Pompe disease pathogenesis.
- To compare infantile Pompe disease pathology with that observed in adult patients.
Main Methods:
- Analysis of single muscle fibers from biopsies of infants before and 6 months after ERT.
- Staining for autophagosomal and lysosomal markers, followed by confocal microscopy.
- Second harmonic imaging of unstained muscle bundles.
Main Results:
- Infants displayed significantly expanded lysosomes, with negligible autophagic components, contrary to adult patients.
- Following 6 months of ERT, autophagic buildup became apparent after glycogen clearance.
- The two pathologies (expanded lysosomes and autophagy) did not appear to coexist in most muscle fibers.
Conclusions:
- Infantile Pompe disease pathogenesis differs from adult forms, characterized initially by lysosomal expansion rather than autophagy.
- Enzyme replacement therapy may reveal underlying autophagic pathology by clearing accumulated glycogen.
- These findings highlight distinct pathological mechanisms in infantile versus adult Pompe disease.
Abstract:
Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase, the enzyme that degrades glycogen in the lysosomes. The disease manifests as a fatal cardiomyopathy and skeletal muscle myopathy in infants; in milder late-onset forms skeletal muscle is the major tissue affected. We have previously demonstrated that autophagic inclusions in muscle are prominent in adult patients and the mouse model. In this study we have evaluated the contribution of the autophagic pathology in infants before and 6 months after enzyme replacement therapy. Single muscle fibers, isolated from muscle biopsies, were stained for autophagosomal and lysosomal markers and analyzed by confocal microscopy. In addition, unstained bundles of fixed muscles were analyzed by second harmonic imaging. Unexpectedly, the autophagic component which is so prominent in juvenile and adult patients was negligible in infants; instead, the overwhelming characteristic was the presence of hugely expanded lysosomes. After 6 months on therapy, however, the autophagic buildup becomes visible as if unmasked by the clearance of glycogen. In most fibers, the two pathologies did not seem to coexist. These data point to the possibility of differences in the pathogenesis of Pompe disease in infants and adults.
Related Concept Videos
Lysosomal Hydrolases
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview

